Literature DB >> 24337375

Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27.

Irina Kochetkova1, Theresa Thornburg, Gayle Callis, Kathryn Holderness, Massimo Maddaloni, David W Pascual.   

Abstract

A Salmonella therapeutic expressing enterotoxigenic Escherichia coli colonization factor Ag I (CFA/I) fimbriae protects against collagen-induced arthritis (CIA) by eliciting two regulatory T cell (Treg) subsets: TGF-β-producing Foxp3(-)CD39(+)CD4(+) T cells and IL-10-producing Foxp3(+)CD39(+)CD4(+) T cells. However, it is unclear whether CFA/I fimbriae alone are protective and whether other regulatory cytokines are involved, especially in the context for the EBI3-sharing cytokines, Treg-derived IL-35 and APC-derived IL-27, both capable of suppressing Th17 cells and regulating autoimmune diseases. Subsequent evaluation revealed that a single oral dose of purified, soluble CFA/I fimbriae protected against CIA as effectively as did Salmonella-CFA/I and found that Foxp3(+)CD39(+)CD4(+) T cells were the source of secreted IL-35, whereas IL-27 production by CD11c(+) cells was inhibited. Inquiring into their relevance, CFA/I fimbriae-treated IL-27R-deficient (WSX-1(-/-)) mice were equally protected against CIA as were wild-type mice, suggesting a limited role for IL-27. In contrast, CFA/I fimbriae-mediated protection was abated in EBI3(-/-) mice, accompanied by the loss of TGF-β- and IL-10-producing Tregs. Adoptive transfer of C57BL/6 CD39(+)CD4(+) T cells to EBI3(-/-) mice with concurrent CFA/I plus IL-35 treatment effectively stimulated Tregs suppressing proinflammatory collagen II-specific Th cells. In contrast, recipients cotransferred with C57BL/6 and EBI3(-/-) CD39(+)CD4(+) T cells and treated with CFA/I plus IL-35 were not protected, implicating the importance of endogenous IL-35 for conferring CFA/I-mediated protection. Thus, CFA/I fimbriae stimulate IL-35 required for the coinduction of TGF-β and IL-10.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24337375      PMCID: PMC3903302          DOI: 10.4049/jimmunol.1302018

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  57 in total

Review 1.  Cytokine pathways and joint inflammation in rheumatoid arthritis.

Authors:  E H Choy; G S Panayi
Journal:  N Engl J Med       Date:  2001-03-22       Impact factor: 91.245

2.  Mechanisms of joint destruction in rheumatoid arthritis.

Authors:  H E Jasin
Journal:  J Orthop Sci       Date:  2000       Impact factor: 1.601

3.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 4.  Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis.

Authors:  Ernest Choy
Journal:  Rheumatology (Oxford)       Date:  2012-07       Impact factor: 7.580

5.  Antigen-specific transforming growth factor β-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance.

Authors:  Ning Kong; Qin Lan; Maogen Chen; Julie Wang; Wei Shi; David A Horwitz; Valerie Quesniaux; Bernhard Ryffel; Zhongmin Liu; David Brand; Hejian Zou; Song Guo Zheng
Journal:  Arthritis Rheum       Date:  2012-08

6.  Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis.

Authors:  V K Tuohy; M Yu; L Yin; P M Mathisen; J M Johnson; J A Kawczak
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

Review 7.  Advances in research on animal models of rheumatoid arthritis.

Authors:  Yiping Hu; Wenxiang Cheng; Wenhong Cai; Ye Yue; Jinchao Li; Peng Zhang
Journal:  Clin Rheumatol       Date:  2012-08-11       Impact factor: 2.980

8.  A novel role for IL-27 in mediating the survival of activated mouse CD4 T lymphocytes.

Authors:  Gisen Kim; Ryo Shinnakasu; Christiaan J M Saris; Hilde Cheroutre; Mitchell Kronenberg
Journal:  J Immunol       Date:  2013-01-18       Impact factor: 5.422

9.  Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response.

Authors:  D W Pascual; D M Hone; S Hall; F W van Ginkel; M Yamamoto; N Walters; K Fujihashi; R J Powell; S Wu; J L Vancott; H Kiyono; J R McGhee
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

10.  IL-10 signaling in CD4+ T cells is critical for the pathogenesis of collagen-induced arthritis.

Authors:  Jian Tao; Masahito Kamanaka; Jianlei Hao; Zhifang Hao; Xi Jiang; Joe E Craft; Richard A Flavell; Zhenzhou Wu; Zhangyong Hong; Liqing Zhao; Zhinan Yin
Journal:  Arthritis Res Ther       Date:  2011-12-22       Impact factor: 5.156

View more
  14 in total

Review 1.  The Gut Microbiome and Multiple Sclerosis.

Authors:  Javier Ochoa-Repáraz; Trevor O Kirby; Lloyd H Kasper
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

Review 2.  Interleukin-35 in immune-related diseases: protection or destruction.

Authors:  Junfeng Zhang; Yunsheng Zhang; Qingpeng Wang; Chunlei Li; Hongxin Deng; Chuanping Si; Huabao Xiong
Journal:  Immunology       Date:  2019-03-07       Impact factor: 7.397

3.  Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Deepa Hammaker; Irina Kochetkova; Andrei I Khlebnikov; Sergey A Lyakhov; Gary S Firestein; Mark T Quinn
Journal:  J Pharmacol Exp Ther       Date:  2015-03-17       Impact factor: 4.030

Review 4.  Interleukin-35: a Potential Therapeutic Agent for Autoimmune Diseases.

Authors:  Shi-Yang Guan; Rui-Xue Leng; Muhammad Imran Khan; Humera Qureshi; Xiang-Pei Li; Dong-Qing Ye; Hai-Feng Pan
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

Review 5.  The influence of gut-derived CD39 regulatory T cells in CNS demyelinating disease.

Authors:  Javier Ochoa-Repáraz; Lloyd H Kasper
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

6.  Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-β-producing CD39+ regulatory T cells.

Authors:  Massimo Maddaloni; Irina Kochetkova; SangMu Jun; Gayle Callis; Theresa Thornburg; David W Pascual
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

7.  Induction of gut regulatory CD39+ T cells by teriflunomide protects against EAE.

Authors:  Javier Ochoa-Repáraz; Sara L Colpitts; Christopher Kircher; Eli J Kasper; Kiel M Telesford; Sakhina Begum-Haque; Anudeep Pant; Lloyd H Kasper
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-10-12

Review 8.  IL-30 (IL-27A): a familiar stranger in immunity, inflammation, and cancer.

Authors:  Booki Min; Dongkyun Kim; Matthias J Feige
Journal:  Exp Mol Med       Date:  2021-05-28       Impact factor: 12.153

9.  Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.

Authors:  Yi-Peng Fu; Yong Yi; Xiao-Yan Cai; Jian Sun; Xiao-Chun Ni; Hong-Wei He; Jia-Xing Wang; Zhu-Feng Lu; Jin-Long Huang; Ya Cao; Jian Zhou; Jia Fan; Shuang-Jian Qiu
Journal:  Br J Cancer       Date:  2016-03-22       Impact factor: 7.640

10.  Allergic Rhinitis and Its Relationship with IL-10, IL-17, TGF-β, IFN-γ, IL 22, and IL-35.

Authors:  P Bayrak Degirmenci; S Aksun; Z Altin; F Bilgir; I B Arslan; H Colak; B Ural; D Solakoglu Kahraman; G Diniz; B Ozdemir; C Kırmaz
Journal:  Dis Markers       Date:  2018-03-06       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.